Findings

What do systematic reviews say?

4,317 questions · 75,239 findings · 5,342 reviews

Sort:Best matchNewestHighest certainty Download CSV

No studies found 15,213 · 20.2%GRADE not reported 10,323 · 13.7%Very low 17,528 · 23.3%Low 17,951 · 23.9%Moderate 11,190 · 14.9%High 3,034 · 4%

Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.

Summary of findings for airway clearance techniques vs no airway clearance techniques

Expectorated secretions (sputum wet weight) · adults and children with cystic fibrosis

1 finding from 1 review

Airway clearance techniques compared to no airway clearance techniques for cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
5 studies · 47 participants
Very low

Summary of findings for airway clearance techniques vs no airway clearance techniques

Exercise capacity · adults and children with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Airway clearance techniques compared to no airway clearance techniques for cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings for airway clearance techniques vs no airway clearance techniques

Outcomes relevant to participants' well‐being · adults and children with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Airway clearance techniques compared to no airway clearance techniques for cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Serenoa repens vs placebo or no intervention

Urologic symptom scores · men with lower urinary tract symptoms secondary to benign prostatic obstruction

Serenoa repens showed no clear difference in urologic symptom scoreMeasured by IPSS scores (range 0 to 35)Higher… compared with placebo or no intervention (high certainty).

1 finding from 1 review

Serenoa repens for the treatment of lower urinary tract symptoms due to benign prostatic enlargement 2023 · Cochrane Headline outcomes only
no estimate extracted
9 studies · 1681 participants
High

Serenoa repens vs placebo or no intervention

QoL · men with lower urinary tract symptoms secondary to benign prostatic obstruction

Serenoa repens showed no clear difference in quality of lifeMeasured by IPSS‐QoL score (range 0 to 6) compared with placebo or no intervention (high certainty).

1 finding from 1 review

Serenoa repens for the treatment of lower urinary tract symptoms due to benign prostatic enlargement 2023 · Cochrane Headline outcomes only
no estimate extracted
5 studies · 1001 participants
High

Serenoa repens vs placebo or no intervention

Adverse eventsCumulative incidence · men with lower urinary tract symptoms secondary to benign prostatic obstruction

Serenoa repens showed no clear difference in adverse eventsCumulative incidence compared with placebo or no intervention (moderate certainty).

1 finding from 1 review

Serenoa repens for the treatment of lower urinary tract symptoms due to benign prostatic enlargement 2023 · Cochrane Headline outcomes only
RR 1.01 [0.77, 1.31]
12 studies · 2399 participants
Moderate

Serenoa repens in combination with other phytotherapy vs placebo or no intervention

Urologic symptom scores · men with lower urinary tract symptoms secondary to benign prostatic obstruction

Serenoa repens in combination with other phytotherapy showed no clear difference in urologic symptom scoreMeasured by IPSS scores (range 0 to 35)Higher… compared with placebo or no intervention (low certainty).

1 finding from 1 review

Serenoa repens for the treatment of lower urinary tract symptoms due to benign prostatic enlargement 2023 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 460 participants
Low

Serenoa repens in combination with other phytotherapy vs placebo or no intervention

QoL · men with lower urinary tract symptoms secondary to benign prostatic obstruction

1 finding from 1 review

Serenoa repens for the treatment of lower urinary tract symptoms due to benign prostatic enlargement 2023 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 265 participants
Very low

Serenoa repens in combination with other phytotherapy vs placebo or no intervention

Adverse eventsCumulative incidence · men with lower urinary tract symptoms secondary to benign prostatic obstruction

Serenoa repens in combination with other phytotherapy showed no clear difference in adverse eventsCumulative incidence compared with placebo or no intervention (low certainty).

1 finding from 1 review

Serenoa repens for the treatment of lower urinary tract symptoms due to benign prostatic enlargement 2023 · Cochrane Headline outcomes only
RR 0.91 [0.58, 1.41]
4 studies · 481 participants
Low

Hypertonic saline 3% to 7% vs Normal saline

FEV1 % predicted: relative change from baseline · adults and children with cystic fibrosis (stable lung disease)

1 finding from 1 review

Nebulised hypertonic saline for cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 246 participants
Very low

Hypertonic saline 3% to 7% vs Normal saline

LCI · adults and children with cystic fibrosis (during acute exacerbations of lung disease)

The review found no eligible studies for this question.

1 finding from 1 review

Nebulised hypertonic saline for cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Hypertonic saline 3% to 7% vs Normal saline

All‐cause mortality · adults and children with cystic fibrosis (during acute exacerbations of lung disease)

1 finding from 1 review

Nebulised hypertonic saline for cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 142 participants
Low

Hypertonic saline 3% to 7% vs Normal saline

Measures of sputum clearance · adults and children with cystic fibrosis (during acute exacerbations of lung disease)

The review found no eligible studies for this question.

1 finding from 1 review

Nebulised hypertonic saline for cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Hypertonic saline 3% to 7% vs Normal saline

Pulmonary exacerbations · adults and children with cystic fibrosis (during acute exacerbations of lung disease)

Hypertonic saline 3% to 7% showed no clear difference in pulmonary exacerbations compared with isotonic saline (low certainty).

1 finding from 1 review

Nebulised hypertonic saline for cystic fibrosis 2023 · Cochrane Headline outcomes only
HR 0.86 [0.57, 1.3]
1 study · 132 participants
Low

Hypertonic saline 3% to 7% vs Normal saline

Adverse events · adults and children with cystic fibrosis (during acute exacerbations of lung disease)

1 finding from 1 review

Nebulised hypertonic saline for cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 142 participants
Very low

Hypertonic saline vs rhDNase with

FEV1 % predicted: relative change from baseline · adults and children with cystic fibrosis

1 finding from 1 review

Nebulised hypertonic saline for cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 14 participants
Very low

Hypertonic saline vs rhDNase with

FEV1 · adults and children with cystic fibrosis

1 finding from 1 review

Nebulised hypertonic saline for cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 47 participants
Very low

Hypertonic saline vs rhDNase with

LCI · adults and children with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Nebulised hypertonic saline for cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Hypertonic saline vs rhDNase with

All‐cause mortality · adults and children with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Nebulised hypertonic saline for cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Hypertonic saline vs rhDNase with

Measures of sputum clearance · adults and children with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Nebulised hypertonic saline for cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found